Methylphenidate is named as an intervention in 11 current clinical trials in our Canada, Israel, France, Sweden, Denmark, Poland, Brazil and Taiwan registers. 11 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sunnybrook Health Sciences Centre (2). The most-studied condition is Methylphenidate. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Methylphenidate. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Methylphenidate for Early Awakening in Coma (MEAWAKE)
2025-524937-19-00 · CTIS ↗ · Nervous System Diseases
|
Phase 2 | Authorised | Rigshospitalet | Austria, Denmark, Germany + 1 more |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
18 single-substance products containing Methylphenidate on the HPRA medicines list.
| Condition (as registered) | Trials |
|---|---|
| Methylphenidate | 2 |
| Alzheimer Disease | 2 |
| Posttraumatic Stress Disorder | 2 |
| Adult ADHD | 1 |
| Adult-onset ADHD With Mood Disorder | 1 |
| ADHD | 1 |
| Brain Tumor, Pediatric | 1 |
| Cancer-related Fatigue | 1 |
| Attention Deficit Disorder with Hyperactivity | 1 |
| Diabetes Mellitus, Type 1 | 1 |
| Chronic Neuropathic Pain | 1 |
| Apathy in Dementia | 1 |
| Dementia | 1 |
| Mild Behavioural Impairment | 1 |
| Alzheimer s Disease | 1 |
| Alzheimer Dementia (AD) | 1 |
| Alzheimer Dementia | 1 |
| Attention Deficit Disorder With Hyperactivity | 1 |
| Metabolomics | 1 |
| PTSD | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
11 current trials in our Canada, Israel, France, Sweden, Denmark, Poland, Brazil and Taiwan registers name Methylphenidate as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 11 of the 11 trials are recruiting: 3 with sites in Canada, 2 with sites in Israel, 1 with sites in France, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Brazil and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sunnybrook Health Sciences Centre (2), University of Haifa (2), University Hospital, Strasbourg, France (1) and Lund University (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 18 single-substance products containing Methylphenidate, for example Concerta XL 27 mg prolonged-release tablets (Janssen Sciences Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 3 entries for Methylphenidate: ADHD medicines (EU: shortage ongoing); US FDA: current; US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Methylphenidate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Methylphenidate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Methylphenidate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.